MPG.eBooks - Description: Clinical review report: Cladribine (Mavenclad) (EMD serono)

Cover Image

Read Now

Clinical review report: Cladribine (Mavenclad) (EMD serono)

The objective of this report is to perform a systematic review of the beneficial and harmful effects of cladribine for the treatment of relapsing-remitting multiple sclerosis

Bibliographic Details
Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, October 2018
Edition:	Version: Final with Redactions
Series:	CADTH common drug review
Subjects:	Cladribine / Therapeutic Use Multiple Sclerosis, Relapsing-remitting / Drug Therapy Treatment Outcome Cladribine / Adverse Effects Immunosuppressive Agents / Therapeutic Use
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK539995
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The objective of this report is to perform a systematic review of the beneficial and harmful effects of cladribine for the treatment of relapsing-remitting multiple sclerosis
Physical Description:	1 PDF file (76 pages) illustrations